Oral Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study

NCT ID: NCT06329063

Last Updated: 2024-04-11

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-05
• Study Completion Date: 2025-07-30

Brief Summary

The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

Detailed Description

Animal models and initial findings in humans suggest a role of the AVP signaling system in socio-emotional processes. At the same time, the visual system's remarkable ability to perceive and interpret impending threats, notably through the "looming" phenomenon- a distinct pattern of optical expansion on the retina as objects approach, theoretically allows for precise estimation of the time-to-collision (TTC). It was recently demonstrated that the affective content of looming stimuli influences perceived TTC, with threatening objects judged as approaching sooner than non-threatening objects, hinting at a nuanced interaction between emotional valence and temporal perception. Within this context the present study aims to validate the effects of orally administered on the perception of time-to-collision of threatening and non-threatening stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of vasopressin (20 IU) or placebo before performing a looming visual stimuli task 45 minutes after administration. The task paradigm will encompass threatening (butterfly, rabbit) and non-threatening (spider, snake) stimuli

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

Vasopressin group

Drug: Vasopressin (20IU)

Group Type: EXPERIMENTAL

Vasopressin

Intervention Type: DRUG

Administration of vasopressin (20 IU) (oral spray)

Placebo group

Drug: Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Administration of placebo (oral spray)

Interventions

Vasopressin

Administration of vasopressin (20 IU) (oral spray)

Intervention Type: DRUG

Placebo

Administration of placebo (oral spray)

Intervention Type: DRUG

Other Intervention Names

Antidiuretic Hormone; Placebo treatment

Eligibility Criteria

Inclusion Criteria

• Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.
• Normal or corrected-normal version

Exclusion Criteria

• History of neuropsychiatric diseases.
• History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
• History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
• History of renal diseases, including renal stones or renal failure.
• History of hyponatremia(Serum sodium <135mmol/L) or hyperkalemia (Serum potassium>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
• Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
• Infections such as COVID-19 or influenza, or unexplained fever.
• Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
• History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Electronic Science and Technology of China

OTHER

Sponsor Role: lead

Responsible Party

Benjamin Becker

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Benjamin Becker, Dr

Role: PRINCIPAL_INVESTIGATOR

University of Electronic Science and Technology of China

Locations

University of Electronic Science and Technology of China

Chengdu, Sichuan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Weihua Zhao, Dr

Role: CONTACT

zarazhao.uestc@outlook.com

86-28-61830811

Facility Contacts

Weihua Zhao, Dr

Role: primary

zarazhao.uestc@outlook.com

86-28-61830811

Other Identifiers

BAM_lab_eyetracking_03

Identifier Type: -

Identifier Source: org_study_id